A biopharma company and a joint venture have turned to the Delaware federal court to seek what it says is its fair share of the billions of dollars in profit generated from Moderna’s COVID-19 vaccine.

A complaint filed Monday alleges Moderna couldn’t have produced its vaccine as fast as it did without Pennsylvania-based Arbutus Biopharma Corp.’s patented mRNA delivery method and says Moderna didn’t ask for permission to license six patents involving nucleic acid-lipid particles, all of which are owned by Arbutus and have exclusive rights held by plaintiff Genevant Sciences GmbH, a Swiss joint venture between Arbutus and Roivant Sciences.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]